BRDG 1 293T Transfected Lysate - (positive control) (ab94204)

Overview

  • Product nameBRDG 1 293T Transfected Lysate - (positive control)
  • General notesab94204 is a 293T cell transfected lysate in which Human BRDG 1 has been transiently over-expressed using a pCMV-BRDG 1 plasmid. The lysate is provided in 1 x Sample Buffer. Note: For more details about how the transfected lysate was prepared view preparation notes
  • Tested applicationsWB more details

Properties

  • BackgroundFunction: In BCR signaling, appears to function as a docking protein acting downstream of TEC and participates in a positive feedback loop by increasing the activity of TEC. Similarity: Contains 1 PH domain. Contains 1 SH2 domain. PTM: Phosphorylated on tyrosine by TEC.

Applications

Our Abpromise guarantee covers the use of ab94204 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Notes
WB
  • Application notesWB: Use at an assay dependent dilution.


    Not yet tested in other applications.
    Optimal dilutions/concentrations should be determined by the end user.
  • BRDG 1 293T Transfected Lysate - (positive control) images

    • ab94204 at 15µg/lane on an SDS-PAGE gel.
    • All lanes : Anti-BRDG 1 antibody (ab57031) at 1/500 dilution

      Lane 1 : BRDG 1 293T Transfected Lysate - (positive control) (ab94204)
      Lane 2 : 293T non-transfected lysate

      Lysates/proteins at 25 µg per lane.

      Secondary
      Goat Anti-mouse IgG (H and L) HRP conjugated at 1/2500 dilution

    References for BRDG 1 293T Transfected Lysate - (positive control) (ab94204)

    ab94204 has not yet been referenced specifically in any publications.

    Product Wall

    There are currently no Questions for ab94204.
    Please use the link above to contact us or submit feedback about this product.

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"